Drug
Sonrotoclax clinical trials
Also written BGB-11417 and Beqalzi.
- studies test it
- 31
- open now
- 22
- in phase 3
- 5
- first study started
- 2020
Keep track of what changes. Save the sonrotoclax studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
29 studies that test it; most in 2026 (13); 2 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 20
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 18
BeOne Medicines (10) · BeiGene (3) · City of Hope Medical Center (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Shanghai Jiao Tong University School of Medicine (1) · Fred Hutchinson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · The First Affiliated Hospital of Soochow University (1)
Often tested with
Tested in the same studies.
Zanubrutinib (11) · Obinutuzumab (4) · BG-71332 (1) · Tacabrutideg (1) · Glofitamab (1) · Gemcitabine (1) · Oxaliplatin (1) · CM336 (1)
Studies
Open first, then newest update. How each study uses sonrotoclax is read from its arms, and is right about nine times in ten.
Testing it · 31
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3BeOne MedicinesNCT06943872Written as Sonrotoclax
- Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Not yet recruitingPhase 2Fred Hutchinson Cancer CenterNCT07887061Written as Sonrotoclax
- Sonrotoclax Plus Azacitidine in Patients With MDS-IB2RecruitingPhase 1/2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07885397Written as Sonrotoclax
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic ImpairmentNot yet recruitingPhase 1BeOne MedicinesNCT07855991Written as Sonrotoclax
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingPhase 2Canadian Cancer Trials GroupNCT07341191Written as Sonrotoclax
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07321652Written as Sonrotoclax
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingPhase 3BeOne MedicinesNCT06742996Written as Sonrotoclax
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingPhase 1/2BeOne MedicinesNCT06697184Written as Sonrotoclax
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as Sonrotoclax
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07799220Written as Sonrotoclax
- Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialNot yet recruitingPhase 2City of Hope Medical CenterNCT07812246Written as Sonrotoclax
- Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter TransformationRecruitingPhase 2German CLL Study GroupNCT04271956Written as Sonrotoclax
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07774234Written as Sonrotoclax
- Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL AmyloidosisRecruitingPhase 2Peking University People's HospitalNCT07335887Written as sonrotoclax
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07687004Written as Sonrotoclax
- A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07674810Written as Sonrotoclax
- Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07638787Written as Sonrotoclax
- A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL PatientsRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07671378Written as Zanubrutinib and sonrotoclax
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingPhase 1City of Hope Medical CenterNCT06859008Written as Sonrotoclax
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaRecruitingPhase 2Christine RyanNCT06854003Written as Sonrotoclax
See all 31 studies that test sonrotoclax →
Given in every arm · 13 — sonrotoclax is usual care beside what is tested
- A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 2M.D. Anderson Cancer CenterNCT07508995Written as BGB-11417
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Sonrotoclax
- A Study of BGB-11417 in Participants With Myeloid MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT04771130Written as BGB-11417
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Sonrotoclax
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2BeOne MedicinesNCT07770698Written as sonrotoclax
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingPhase 2Massachusetts General HospitalNCT06849713Written as Sonrotoclax
- Study of SA+X in the Treatment of Newly Diagnosed AMLRecruitingPhase 2Ruijin HospitalNCT07548710Written as Sonrotoclax
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07573670Written as BCL-2 indibitor
- Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06839053Written as Sonrotoclax
- Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL PatientsRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06463691Written as BGB-11417
- A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingPhase 2BeOne MedicinesNCT05952037Written as Sonrotoclax
- Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesActive, not recruitingPhase 1BeOne MedicinesNCT04277637Written as Sonrotoclax
- A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy VolunteersCompletedPhase 1BeiGeneNCT06543043Written as sonrotoclax
Codes
What other systems call sonrotoclax · ClinicalTrials.gg INT014564
- UNII (FDA) 30R67U9KYSSONROTOCLAXConfirmed FDA, Wikidata
- Wikidata Q131412176sonrotoclaxConfirmed FDA, Wikidata
- NCI Thesaurus C175489SonrotoclaxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 30R67U9KYS | SONROTOCLAX | Confirmed FDA, Wikidata |
| Wikidata | Q131412176 | sonrotoclax | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175489 | Sonrotoclax | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.